Skip to main content

Table 2 Patient characteristics

From: Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: The OITA-GF study 2

  Group F (n = 31) Group L (n = 47) p value
Age (years) 72.0 ± 9.3 74.6 ± 8.8 0.22
Male 26 (83.9%) 32 (68.1%) 0.19
Body mass index (kg/m2) 23.8 ± 3.4 24.3 ± 3.6 0.50
Hypertension 25 (80.6%) 44 (93.6%) 0.14
Diabetes mellitus 9 (29.0%) 18 (38.3%) 0.47
Current smoking 0 (0%) 2 (4.3%) 0.52
Daily alcohol drinking 12 (38.7%) 13 (27.7%) 0.33
Coronary artery disease 26 (83.9%) 43 (91.5%) 0.47
Prior percutaneous coronary intervention 25 (80.6%) 39 (83.0%) 1.0
Prior coronary bypass surgery 1 (3.2%) 2 (4.3%) 1.0
Prior stroke 4 (12.9%) 4 (8.5%) 0.71
Atrial fibrillation 6 (19.4%) 7 (14.9%) 0.76
History of gastroduodenal ulcer 5 (16.1%) 9 (19.1%) 0.77
History of eradication of H. pylori 3 (9.7%) 5 (10.6%) 1.0
Gastrointestinal symptom rating scale    
  Reflux symptom score 1.4 ± 0.6 1.3 ± 0.6 0.19
  Abdominal pain score 1.4 ± 0.7 1.2 ± 0.5 0.32
  Indigestion score 1.4 ± 0.6 1.6 ± 0.6 0.24
Positive urinary H. pylori antibodies 15 (48.4%) 22 (46.8%) 1.0
Duration of lansoprazole or famotidine treatment    0.76
  <1 year 7 (14.9%) 6 (19.4%)  
  ≥1 year(s) 40 (85.1%) 25 (80.6%)  
Dose of aspirin    1.0
  81 mg/day 1 (3.2%) 2 (4.3%)  
  100 mg/day 30 (96.8%) 45 (95.7%)  
Type of aspirin    1.0
  Enteric-coated formulation 30 (96.8%) 45 (95.7%)  
  Buffered formulation 1 (3.2%) 2 (4.3%)  
Other antiplatelet agents 12 (38.7%) 17 (36.2%) 1.0
Warfarin 8 (25.8%) 8 (17.0%) 0.40
Dabigatran 2 (7.4%) 2 (4.3%) 0.62
Nitrates 10 (32.3%) 16 (34.0%) 1.0
Calcium antagonists 14 (45.2%) 26 (55.3%) 0.49
Angiotensin-converting enzyme inhibitors 3 (9.7%) 4 (8.5%) 1.0
Angiotensin receptor blockers 14 (45.2%) 30 (63.8%) 0.16
Statins 27 (87.1%) 42 (89.4%) 1.0
  1. The data are presented as the mean ± SD or number (%).